Sensing Bad: Are Co-stimulatory CAR-Expressing γδ T Cells Safer?

Slides:



Advertisements
Similar presentations
Jennifer G. Cheung, Krystyna Konopka, Nejat Düzgünes
Advertisements

Suzanne L. Topalian, Charles G. Drake, Drew M. Pardoll  Cancer Cell 
The Principles of Engineering Immune Cells to Treat Cancer
Socializing Individualized T-Cell Cancer Immunotherapy
Volume 12, Issue 5, Pages (November 2005)
414. A Novel Clinical Severity Scoring Measure in Canine X-Linked Myotubular Myopathy: Results Following Systemic AAV Gene Replacement    Molecular Therapy 
209. Use of Helicobacter pyroli Neutrophil Activating Protein (NAP) as an Immune- Modulatory Agent To Enhance the Efficacy of Oncolytic Adenovirus Therapy.
Man's Best Friend: Utilizing Naturally Occurring Tumors in Dogs to Improve Chimeric Antigen Receptor T-cell Therapy for Human Cancers  Melinda Mata, Stephen.
Engineering Natural Killer Cells for Cancer Immunotherapy
Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma
Genome-editing Technologies for Gene and Cell Therapy
Molecular Genetics of Pediatric Soft Tissue Tumors
627. Non-Invasive, Multimodal Imaging of Microvesicles with Metabolically Biotinylated, Membrane-Bound Gaussia Luciferase    Molecular Therapy  Volume.
Will Engineered T Cells Expressing CD20 scFv Eradicate Melanoma?
Mechanisms of Drug-Induced Allergy
162. Stability of Polymer/Plasmid DNA Complexes In Vitro and In Vivo
281. Rapid Generation of Induced Pluripotent Stem Cells (iPSCs) from the Urine of a Patient with Duchenne Muscular Dystrophy    Molecular Therapy  Volume.
Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma
Daniel Abate-Daga, Marco L Davila  Molecular Therapy - Oncolytics 
Direct Conversion of Skin Cells into Blood: Alchemy or Science?
Molecular Therapy  Volume 20, Pages S261-S262 (May 2012) DOI: /S (16)
Evolving Gene Therapy in Primary Immunodeficiency
343. Benchtop DNA Synthesizer: Oligo-Templated Polymerization (OTP)
Engineering Natural Killer Cells for Cancer Immunotherapy
John R. Martin, Christopher E. Nelson, Mukesh K
Volume 26, Issue 2, Pages (February 2018)
HIV Receives a “One Two Knockout Punch”
Volume 25, Issue 5, Pages (May 2017)
Volume 25, Issue 1, Pages 5-7 (January 2017)
Xiuyan Wang, Isabelle Rivière  Molecular Therapy - Oncolytics 
Volume 25, Issue 5, Pages (May 2017)
The Other Face of Chimeric Antigen Receptors
724. Blood-Derived Endothelial Progenitor Cells Can Be Isolated With a Novel Method of Diluted Whole Blood Incubation with AMD3100-Induced Mobilization.
Research Techniques Made Simple: CAR T-Cell Therapy
Genome-editing Technologies for Gene and Cell Therapy
Valder R Arruda, Patricia Favaro, Jonathan D Finn  Molecular Therapy 
The Principles of Engineering Immune Cells to Treat Cancer
Premal Lulla, Carlos A. Ramos  Molecular Therapy 
Molecular Therapy  Volume 20, (May 2012) DOI: /S (16)
Molecular Therapy  Volume 7, Issue 5, (May 2003) DOI: /S (16)
847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach    Molecular.
Designer Lipids Advance Systemic siRNA Delivery
Volume 25, Issue 5, Pages (May 2017)
133. Survival with Normal Neurological Development of the Juvenile Lethal Urea Cycle Defect Arginase Deficient Mouse with AAV Gene Therapy    Molecular.
660. Bowel/Bladder Sensation and Control in Patients with Spinal Cord Injury Treated with Human Embryonic Stem Cell Therapy  Geeta Shroff  Molecular Therapy 
Volume 26, Issue 2, Pages (February 2018)
68. Site Specific Intra-Placental Gene Transfer Corrects Fetal Growth Restriction in a Novel Mouse Model of Placental Insufficiency (PI)    Molecular.
521. Multiplex Genome Editing of TCR°/CD52 Genes as a Platform for “Off the Shelf” Adoptive T-Cell Immunotherapies    Molecular Therapy  Volume 22, Pages.
Jennifer G. Cheung, Krystyna Konopka, Nejat Düzgünes
405. Hindlimb and Forelimb Strength Assessment in a Canine Model of X-Linked Myotubular Myopathy Following AAV-Mediated Gene Replacement    Molecular.
Volume 26, Issue 4, Pages (April 2018)
674. Molecular, Biochemical and Biomechanical Analysis of Articular Cartilage Repaired with Genetically Modified Chondrocytes Expressing Insulin-Like.
Clinical Trials of Adenovirus-mediated Therapy for Glioma
Molecular Therapy  Volume 18, Pages S260-S261 (May 2010) DOI: /S (16)
In This Issue Molecular Therapy Volume 16, Issue 4, (April 2008)
372. Targeted Mutagenesis of Ubiquitin-Binding Lysine Residues on the Adeno- Associated Virus (AAV)2 Capsid Improves Its Transduction Efficiency    Molecular.
521. AAV Immunotherapy Induces Functional Antigen Specific Regulatory T-Cells to a Neuroantigen: A Potential Treatment for MS  Brad E. Hoffman  Molecular.
773. Detection of RNA Interference (RNAi) Mediated mRNA Cleavage in Fresh Injected Tumor Tissue from Patients in a Phase I Trial of pbi-shRNA™ Lipoplex.
740. Prevention of Radiation-Induced Lung Injury by Administration of Gene-Modified Mesenchymal Stem Cells    Molecular Therapy  Volume 20, Pages S285-S286.
Molecular Therapy  Volume 21, Pages S247-S248 (May 2013)
Vanadium: A Panacea for Resistance to Oncolytic Immunotherapy?
Shigeki Yagyu, Malcolm K. Brenner
86. A Highly Compact Epitope-Based Marker Suicide Gene for Safer and Easier Adoptive T-Cell Gene Therapy    Molecular Therapy  Volume 20, Pages S35-S36.
Releasing the Brakes on Cancer Immunotherapy
Volume 26, Issue 5, Pages (May 2018)
297. Minimally Invasive Implantation of Autologous Chondrocytes Transduced with rAAV5-IGF-I Improves Longterm Cartilage Repair in Full-Thickness Chondral.
Jingxian Feng, Jiawen Wang, Junsheng Lin, Yong Diao
Shirley Wong, Roderick A. Slavcev
γδ T Cells and the Lymphoid Stress-Surveillance Response
624. Randomized Phase II Trial of Adjuvant Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer: Preliminary Results    Molecular.
Presentation transcript:

Sensing Bad: Are Co-stimulatory CAR-Expressing γδ T Cells Safer? Robin Parihar  Molecular Therapy  Volume 25, Issue 5, Pages 1064-1066 (May 2017) DOI: 10.1016/j.ymthe.2017.04.012 Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions

Figure 1 “Co-stimulation Only” CAR-γδ T Cell Activation after Recognition of Two Separate Tumor-Associated Molecules The cytotoxic capacity of CD3ζ (signal 1) is mediated through the native γδ-TCR recognizing the tumor-associated danger signal, IPP, while co-stimulation (signal 2) is provided by a CAR recognizing the GD2 solid tumor antigen with an endodomain consisting of the innate NKG2D signaling molecule, DAP10. Normal healthy tissue does not express IPP and thus does not activate γδ T cells through their TCR. Molecular Therapy 2017 25, 1064-1066DOI: (10.1016/j.ymthe.2017.04.012) Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions